Biophytis Reports Audited 2025 Financial Results and Stock Trading Resumption

Biophytis, a biotechnology firm based in Paris and Cambridge, has announced the completion of its financial statements for 2025, now audited and approved by the board. Trading of Biophytis shares has resumed on Euronext Growth Paris. However, auditors were unable to issue an unqualified opinion due to concerns about the company's future viability and capital transaction accounting.

The company reported a net loss of €8.2 million for 2025, a €1.2 million improvement from 2024. Operating expenses dropped by 20%, leading to a 12% better operating income. Financial income increased by 62% due to decreased financial costs.

Cash reserves stood at €187,000 at the end of 2025, a notable increase from the previous year. Despite these improvements, financial uncertainty persists, with funding only secure through September 30, 2026.